STADA Arzneimittel Aktiengesellschaft is a Germany-based pharmaceutical company specializing in the development, manufacturing and marketing of generic medicines and over-the-counter (OTC) healthcare products. Headquartered in Bad Vilbel near Frankfurt, STADA operates a network of production sites, research facilities and sales offices across Europe, Latin America and parts of Asia, serving more than 100 countries worldwide.
The company’s product portfolio encompasses a broad range of therapeutic areas, including pain management, cardiovascular care, central nervous system treatments, dermatology and respiratory medicines. In the generics segment, STADA offers off-patent prescription drugs under its own labels and through licensing partnerships. Its consumer healthcare division markets well-known OTC brands, such as analgesics, allergy remedies and self-care solutions for digestive health.
STADA also provides contract development and manufacturing services (CDMO) for third-party pharmaceutical and biotech customers, leveraging its formulation expertise and production capacity. This business line complements its core offerings by supporting clients with product development, regulatory filings and scalable manufacturing at global sites.
Founded in 1895, STADA transitioned from a regional German firm to an international player over the course of the 20th and early 21st centuries. After listing on the Frankfurt Stock Exchange, the company was taken private in 2017 through a consortium of private-equity investors. Today, it is guided by an experienced management board based at its headquarters, with a focus on expanding its generic and consumer healthcare footprints in established and emerging markets.
AI Generated. May Contain Errors.
Free STDAF Stock Alerts